Stockscreener 앱 받기
14.58
6.54%
-1.02
시장 영업 전:
14.74
0.16
+1.10%
전일 마감가:
$15.60
열려 있는:
$15.63
하루 거래량:
1.01M
Relative Volume:
0.94
시가총액:
$728.33M
수익:
-
순이익/손실:
$-156.39M
주가수익비율:
-3.9512
EPS:
-3.69
순현금흐름:
$-123.06M
1주 성능:
-5.26%
1개월 성능:
+24.83%
6개월 성능:
+69.34%
1년 성능:
+1.32%
1일 변동 폭
$14.48
$15.63
1주일 범위
$14.48
$15.97
52주 변동 폭
$7.30
$16.32
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
명칭
Kalvista Pharmaceuticals Inc
전화
(857) 999-0075
주소
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
KALV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
14.58 | 779.28M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-31 | 개시 | JMP Securities | Mkt Outperform |
| 2025-01-07 | 개시 | TD Cowen | Buy |
| 2024-12-18 | 개시 | BofA Securities | Buy |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2019-07-29 | 개시 | SVB Leerink | Outperform |
| 2019-03-20 | 개시 | Needham | Buy |
| 2018-10-30 | 개시 | Jefferies | Buy |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 개시 | BTIG Research | Buy |
모두보기
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
What institutional investors are buying KalVista Pharmaceuticals Inc. stockUnlock daily market insights for better trades - jammulinksnews.com
What is the dividend policy of KalVista Pharmaceuticals Inc. stockBreakthrough investment results - jammulinksnews.com
What are analysts’ price targets for KalVista Pharmaceuticals Inc. in the next 12 monthsUnlock high-yield investment opportunities - jammulinksnews.com
KalVista Pharmaceuticals Faces Downgrade Due to Shrinking Market and Oral Competitor Threat - AInvest
KalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade) - Seeking Alpha
EMA’s CHMP adopts five orphans - BioCentury
What analysts say about KalVista Pharmaceuticals Inc. stock outlookPhenomenal capital gains - jammulinksnews.com
New medicines recommended for approval by EMA’s CHMP - The Pharma Letter
What analysts say about KalVista Pharmaceuticals Inc. stockFree Daily Trading Room Entry - Autocar Professional
KalVista receives CHMP opinion recommending sebetralstat marketing authorization - TipRanks
KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha
European regulator recommends approval of first oral HAE treatment - Investing.com India
KalVista Pharma Announces Positive CHMP Opinion For Sebetralstat - Nasdaq
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks - Business Wire
What drives KalVista Pharmaceuticals Inc. stock priceFree Daily Trading Room Entry - PrintWeekIndia
US FDA Cancer Reviewers Heading For The Exits, Potentially Impacting Review Timelines - insights.citeline.com
KalVista Pharmaceuticals Inc. Stock Analysis and ForecastRobust investment performance - jammulinksnews.com
Is KalVista Pharmaceuticals Inc. a good long term investmentRapid return acceleration - jammulinksnews.com
Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com
Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP By Investing.com - Investing.com South Africa
Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP - Investing.com India
(KALV) Proactive Strategies - news.stocktradersdaily.com
JMP reiterates Market Outperform rating on Kalvista stock after UK approval By Investing.com - Investing.com South Africa
JMP reiterates Market Outperform rating on Kalvista stock after UK approval - Investing.com Nigeria
KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - BioSpace
KalVista Pharmaceuticals Gets UK Approval for Hereditary Angioedema Treatment - MarketScreener
KalVista Pharmaceuticals announces UK MHRA approval of Ekterly (sebetralstat) - MarketScreener
KalVista gets UK nod for Ekterly (KALV:NASDAQ) - Seeking Alpha
UK approves first oral treatment for hereditary angioedema attacks By Investing.com - Investing.com Canada
(sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
MHRA approves Ekterly to treat HAE - The Pharma Letter
KalVista Pharmaceuticals Wins UK Approval for Hereditary Angioedema Treatment - MarketScreener
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Have Insiders Sold KalVista Pharmaceuticals Shares Recently? - simplywall.st
The week in pharma: action, reaction and insight – week to July 11 - The Pharma Letter
Kalvista Pharmaceuticals Inc (KALV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
0.22%
자본화:
|
볼륨(24시간):